0000000000765482

AUTHOR

Martin Michaud

showing 1 related works from this author

Abatacept as Adjunctive Therapy in Refractory Polymyalgia Rheumatica.

2021

Glucocorticoids (GCs) are the mainstay of treatment for patients with polymyalgia rheumatica (PMR).1 Despite their efficacy, GCs are associated with well-known adverse events and a substantial proportion of patients with PMR do not respond adequately, or are refractory, to initial GC treatment. GC-sparing agents in PMR are limited to methotrexate (MTX).1.

musculoskeletal diseasesmedicine.medical_specialtyeducationImmunologyGiant Cell ArteritisPolymyalgia rheumaticaAbataceptDiagnosis DifferentialRheumatologyRefractoryimmune system diseasesInternal medicinemedicineImmunology and AllergyHumansskin and connective tissue diseasesAdverse effectbusiness.industryAbataceptmedicine.diseaseCombined Modality TherapyPolymyalgia RheumaticaMethotrexatebusinesshormones hormone substitutes and hormone antagonistsmedicine.drugThe Journal of rheumatology
researchProduct